Stryker Co. (SYK) Shares Bought by Argent Trust Co

Argent Trust Co lifted its position in Stryker Co. (NYSE:SYK) by 4.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,999 shares of the medical technology company’s stock after buying an additional 240 shares during the quarter. Argent Trust Co’s holdings in Stryker were worth $941,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Landsberg Bennett & Dubbaneh LLC purchased a new stake in shares of Stryker in the 4th quarter valued at $1,926,000. Moody Lynn & Lieberson LLC raised its holdings in shares of Stryker by 50.8% in the 3rd quarter. Moody Lynn & Lieberson LLC now owns 75,135 shares of the medical technology company’s stock valued at $13,350,000 after buying an additional 25,316 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Stryker in the 3rd quarter valued at $26,368,000. Banco Santander S.A. purchased a new stake in shares of Stryker in the 3rd quarter valued at $3,169,000. Finally, First Citizens Bank & Trust Co. raised its holdings in shares of Stryker by 318.9% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 6,840 shares of the medical technology company’s stock valued at $1,216,000 after buying an additional 5,207 shares during the period. Hedge funds and other institutional investors own 74.99% of the company’s stock.

Several research analysts recently commented on the company. Credit Suisse Group raised Stryker to an “outperform” rating in a research note on Thursday, January 31st. SunTrust Banks boosted their target price on Stryker to $205.00 and gave the stock a “positive” rating in a research note on Monday, February 4th. Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $199.00 target price for the company in a research note on Monday, February 4th. Canaccord Genuity boosted their target price on Stryker from $185.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, January 30th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Stryker in a research note on Friday, November 9th. Seven investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Stryker currently has a consensus rating of “Buy” and an average target price of $185.37.

In other news, VP M Kathryn Fink sold 180 shares of the company’s stock in a transaction dated Monday, February 4th. The stock was sold at an average price of $176.77, for a total transaction of $31,818.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Bijoy Sagar sold 2,361 shares of the company’s stock in a transaction dated Friday, December 7th. The stock was sold at an average price of $171.24, for a total value of $404,297.64. Following the transaction, the vice president now directly owns 2,361 shares of the company’s stock, valued at $404,297.64. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 43,259 shares of company stock valued at $7,515,747. Insiders own 7.30% of the company’s stock.

NYSE:SYK opened at $185.54 on Friday. The stock has a market cap of $68.34 billion, a PE ratio of 25.38, a price-to-earnings-growth ratio of 2.25 and a beta of 0.86. Stryker Co. has a 1 year low of $144.75 and a 1 year high of $186.75. The company has a quick ratio of 1.41, a current ratio of 2.02 and a debt-to-equity ratio of 0.72.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.15 by $0.03. The business had revenue of $3.80 billion during the quarter, compared to analysts’ expectations of $3.73 billion. Stryker had a return on equity of 27.60% and a net margin of 26.12%. As a group, research analysts forecast that Stryker Co. will post 8.12 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, March 28th. This represents a $2.08 annualized dividend and a dividend yield of 1.12%. Stryker’s dividend payout ratio is currently 28.45%.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://sportsperspectives.com/2019/02/15/stryker-co-syk-shares-bought-by-argent-trust-co.html.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Further Reading: How Do Investors Open a Backdoor Roth IRA?

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.